<DOC>
	<DOCNO>NCT00073489</DOCNO>
	<brief_summary>The objective study evaluate safety efficacy OSI-461 CLL patient .</brief_summary>
	<brief_title>A Pilot Study OSI-461 Patients With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>The primary objective study determine activity OSI-461 give twice daily orally previously untreated CLL patient . The secondary objective evaluate safety profile OSI-461 patient population .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Diagnosis CLL establish bone marrow aspiration biopsy flow cytometry peripheral blood . No previous therapy CLL . Expected remain life span great equal six month . 18 year old . Willingness ability sign inform consent . Other active malignancy history treatment malignancy ( exclude nonmelanoma skin cancer ) within previous three year . History malignancy could affect diagnosis assessment OSI461 . Previous therapy CLL . Use investigational medication device within one month initiate study therapy . Concurrent immunotherapy . Use steroids time enrollment ( patient require steroid enrollment may remain study ) . Any condition medication may interfere conduct study . Serious uncontrolled intercurrent medical psychiatric illness , include serious infection . Evidence CNS involvement . Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>chronic leukemia</keyword>
	<keyword>leukemia</keyword>
	<keyword>CLL</keyword>
</DOC>